Hinge Health Beats Q1, But $38M Insider Sell-Off Looms

Forward-Looking Analysis

Hinge Health (HNGE) is expected to report its 2026Q2 financial results on August 4, 2026, with a consensus earnings per share (EPS) estimate of $0.55, representing a significant improvement from the -$7.37 EPS reported in the same quarter last year. While specific revenue forecasts for Q2 are not explicitly detailed in the provided data, total revenue for the trailing twelve months (TTM) stands at $646.34 million, with Q2 revenue previously recorded at $139.10 million, showing a 12.33% increase since the last quarter. The company is projected to see earnings growth of 35.04% over the coming year, with EPS expected to rise from $1.37 to $1.85 per share. Analyst sentiment remains overwhelmingly positive, with 16 research reports issued in the past 90 days. Stifel raised its price target to $90, citing strong growth, while Truist Financial increased its target to $85. Other firms, including Citizens JMP, set a target of $96, and Canaccord Genuity anticipates stock price rises. The consensus 12-month price target is $86.07, indicating approximately 15.3% upside from current levels, supported by a moderate buy consensus rating based on 17 analyst ratings, including 15 buys and 2 strong buys.

Historical Performance Review

In 2026Q1, Hinge Health delivered robust financial results, reporting revenue of $182.31 million and a net income of $35.13 million. The company achieved an EPS of $0.43, significantly beating estimates of $0.34 by 32.35%. Gross profit for the quarter was recorded at $154.23 million, demonstrating strong margin expansion and operational efficiency as the digital healthcare provider continues to scale its AI-driven musculoskeletal care platform.

Additional News

Hinge Health has recently expanded its HingeSelect platform to include surgical care, delivering a fully integrated musculoskeletal care solution. The company also raised its 2026 outlook ahead of its Investor Day, signaling confidence in its growth trajectory. Market analysts have actively upgraded their views, with Stifel reiterating a buy rating and raising targets, while Truist Financial highlighted the company's growth outlook. Despite this positive momentum, insiders have engaged in significant selling activity, with major shareholders selling over $38 million in stock in July 2026. Short interest has decreased by 7.03% to 9.94% of the float, suggesting improving investor sentiment. The company maintains a market cap of approximately $5.75 billion and continues to leverage its AI-powered TrueMotion platform to automate care for joint and muscle health.

Summary & Outlook

Hinge Health demonstrates strong financial health with accelerating revenue growth and a return to profitability in early 2026. Key growth catalysts include the expansion of its AI-driven platform into surgical care and broadening payer partnerships, supported by unanimous analyst upgrades and rising price targets. However, insider selling presents a minor risk factor. Overall, the company's trajectory is bullish, driven by its dominant position in digital MSK care and improving unit economics, positioning it for sustained long-term value creation despite near-term volatility.